Answers are grounded in this paper and cite their sources.
Comparative study reports 12-month outcomes of two paclitaxel-coated balloon systems in de novo coronary artery lesions, highlighting therapeutic options for small vessel disease.
In percutaneous coronary intervention (PCI) of de novo lesions, drug-coated balloons (DCB) have been shown to be a promising strategy to improve clinical outcomes of patients with small vessel disease. Evidence of this strategy in PCI of de novo coronary lesions in a real-world setting is limited. The objective of this study was to compare the 12-month outcomes of 2 paclitaxel-coated balloon systems for the treatment of all de novo coronary artery lesions.
No takes yet. Share an insight, caveat, or question.
Fong et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: